site stats

Cytokinetics pharmaceuticals stock

WebApr 6, 2024 · Company. Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and … WebNov 30, 2024 · PDUFA Target Action Date Set for November 30, 2024. FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has …

China Universal Asset Management Co. Ltd. Lowers Holdings in ...

WebStock analysis for Cytokinetics Inc (CYTK:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. WebMar 6, 2024 · PRESENTATIONS Cytokinetics, Inc. INVESTORS & MEDIA PRESENTATIONS NASDAQ : CYTK $35.19 +0.98 (+2.86%) Mar 31 2024 4:00 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART SHAREHOLDER TOOLS Print Page Email Alerts IR/Media Contacts dr fields boston legal https://treschicaccessoires.com

Cytokinetics (CYTK) Dips 20% so Far in 2024 on Setbacks - Yahoo …

WebMar 16, 2024 · Cytokinetics, Incorporated Common Stock (CYTK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. WebApr 13, 2024 · China Universal Asset Management Co. Ltd. trimmed its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 96.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.The institutional investor owned 961 shares of the biopharmaceutical … WebOct 27, 2024 · Blum acknowledges some CYTK stock investors are watching for a possible Cytokinetics buyout after Bristol Myers spent north of $13 billion to acquire MyoKardia … enkore active software

CYTOKINETICS IN THE NEWS Cytokinetics, Inc.

Category:Cytokinetics Muscle Biology Therapies Home

Tags:Cytokinetics pharmaceuticals stock

Cytokinetics pharmaceuticals stock

Pipeline - Cytokinetics

WebGet the latest Cytokinetics, Inc. (CYTK) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and … WebJul 1, 2024 · The initial conversion price represents a premium of 30.0% over the last reported sale price of $39.29 per share of Cytokinetics’ common stock on June 30, 2024. The conversion rate and...

Cytokinetics pharmaceuticals stock

Did you know?

WebMar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference Apr 17, 2024 10:00 AM EDT Keyword Search Press Release Archive 1998-2005 Year 2024 Apr 11 2024 5:00 pm EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART WebDec 20, 2024 · The CSPAs provide for the sale and issuance to the RTW Investors of 511,182 shares of Cytokinetics common stock of (the "Shares") with an aggregate purchase price of $20.0 million at a price per share of $39.125. The closing will occur on December 20, 2024.

WebFeb 17, 2024 · In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company’s shares closed … WebCytokinetics is led by a team of seasoned industry veterans with the shared objective to create the next great biopharmaceutical company that has the potential to change patients’ lives. With significant depth of industry experience and highly complementary skills in diverse fields including drug discovery, clinical research, business ...

WebMar 31, 2024 · Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function. WebDec 9, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.

WebApr 11, 2024 · Discover historical prices for CYTK stock on Yahoo Finance. View daily, weekly or monthly format back to when Cytokinetics, Incorporated stock was issued.

WebNov 8, 2024 · Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional $18.0 million aggregate principal amount of the notes in connection with the offering, solely to cover... enkor all home theaterWebNov 3, 2024 · Cytokinetics (CYTK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $0.95 per share a year ago. enkor competitionWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Our Vision Leadership … dr fields barnes jewish hospitalWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has … enkore active mouse softwareWebJan 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. dr fields cardiologyWebApr 9, 2024 · Cytokinetics Trading Up 0.7 %. Cytokinetics stock opened at $36.42 on Friday. The business’s 50 day simple moving average is $39.79 and its 200 day simple moving average is $42.22. enkoway.com.cnWeb12 hours ago · In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics. The company’s shares closed last Thursday at … dr fields cherry hill